Improved outcome in HLA-identical sibling hematopoietic stem-cell transplantation for acute myelogenous leukemia predicted by KIR and HLA genotypes.
Inhibitory killer immunoglobulin (Ig)-like receptors (KIRs) recognize HLA-C and -B epitopes on target cells, thereby regulating natural killer (NK) cell activity. In 178 patients receiving T-cell-depleted HLA-identical sibling transplants for acute myelogenous leukemia (AML), chronic myelogenous leukemia (CML), acute lymphoblastic leukemia (ALL), or myelodysplastic syndrome (MDS), analysis of donor KIR genotype with HLA genotype demonstrated that 62.9% of the patients lacked an HLA ligand for donor-inhibitory KIR. Lack of HLA ligand for donor-inhibitory KIR (missing KIR ligand) had no effect on disease-free survival (DFS), overall survival (OS), or relapse in patients receiving transplants for CML and ALL. In patients with AML and MDS, however, there was a significant missing KIR ligand effect on DFS (P = .014; hazard ratio [HR], 0.53; 95% confidence interval [95% CI], 0.28-0.88) and OS (P = .03; HR, 0.53; 95% CI, 0.3-0.93). Incidence of relapse was also lower in patients with AML and MDS who lacked the HLA ligand for donor-inhibitory KIR (P = .04; HR, 0.41; 95% CI, 0.18-0.97). AML and MDS patients lacking 2 HLA ligands for donor-inhibitory KIR had the highest DFS (P = .002) and OS (P = .003). There was no significant contribution of donor-activating KIR to transplantation outcome in these patients. These data indicate that the absence of class I ligand in the recipient for donor-inhibitory KIR can be a prognostic factor for transplantation outcome in HLA-identical sibling transplantation and that the lack of HLA-C or -B ligands for donor-inhibitory KIR can contribute to improved outcomes for patients with AML and MDS.
Hsu
Katharine C
KC
Allogeneic Marrow Transplantation Service and the Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York 10021, USA. hsuk@mskcc.org <hsuk@mskcc.org>
Keever-Taylor
Carolyn A
CA
Wilton
Andrew
A
Pinto
Clara
C
Heller
Glenn
G
Arkun
Knarik
K
O'Reilly
Richard J
RJ
Horowitz
Mary M
MM
Dupont
Bo
B
D000465:Algorithms; D000483:Alleles; D001854:Bone Marrow Cells / Q000276:immunology; D018572:Disease-Free Survival; D000939:Epitopes; D005192:Family Health; D005260:Female; D005838:Genotype; D006085:Graft Survival; D006680:HLA Antigens / Q000276:immunology*; D015235:HLA-B Antigens / Q000276:immunology*; D015236:HLA-C Antigens / Q000276:immunology*; D018380:Hematopoietic Stem Cell Transplantation / Q000379:methods*; D006412:Hematopoietic Stem Cells / Q000276:immunology; D006801:Humans; D007694:Killer Cells, Natural / Q000276:immunology; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics / Q000628:therapy; D015470:Leukemia, Myeloid, Acute / Q000235:genetics* / Q000628:therapy*; D008024:Ligands; D008297:Male; D009190:Myelodysplastic Syndromes / Q000235:genetics / Q000628:therapy; D015345:Oligonucleotide Probes / Q000737:chemistry; D016133:Polymerase Chain Reaction; D054198:Precursor Cell Lymphoblastic Leukemia-Lymphoma / Q000235:genetics / Q000628:therapy; D016016:Proportional Hazards Models; D011971:Receptors, Immunologic / Q000235:genetics* / Q000276:immunology*; D054340:Receptors, KIR; D012008:Recurrence; D012189:Retrospective Studies; D012306:Risk; D013601:T-Lymphocytes / Q000276:immunology; D013997:Time Factors; D016896:Treatment Outcome
D000939:Epitopes; D006680:HLA Antigens; D015235:HLA-B Antigens; D015236:HLA-C Antigens; D008024:Ligands; D015345:Oligonucleotide Probes; D011971:Receptors, Immunologic; D054340:Receptors, KIR
Tissue Antigens. 1995 Nov;46(5):355-67
8838344
Br J Haematol. 2000 Mar;108(4):778-83
10792283
Tissue Antigens. 2000 Oct;56(4):313-26
11098931
Immunology. 2002 Jul;106(3):373-80
12100725
Immunogenetics. 2002 Nov;54(8):543-50
12439616
Int J Hematol. 2003 May;77(4):399-407
12774932
Blood. 1999 Jan 15;93(2):467-80
9885208
J Exp Med. 1996 Apr 1;183(4):1817-27
8666938
J Immunol. 2004 Oct 1;173(7):4273-6
15383555
J Immunol. 2004 Jan 1;172(1):644-50
14688377
Immunogenetics. 2002 Mar;53(12):1009-19
11904677
Immunity. 1997 Dec;7(6):739-51
9430220
Annu Rev Immunol. 2002;20:217-51
11861603
Genes Immun. 2002 Apr;3(2):86-95
11960306
Immunology. 1997 Dec;92(4):567-70
9497500
J Immunol. 2002 Mar 1;168(5):2307-15
11859120
Blood. 1990 Jun 1;75(11):2250-62
2189508
Science. 2004 Aug 6;305(5685):872-4
15297676
Blood. 2005 Mar 15;105(6):2594-600
15536148
J Immunol. 2002 Jul 1;169(1):239-47
12077250
Tissue Antigens. 2001 Jan;57(1):46-54
11169258
J Immunol. 1997 Jun 1;158(11):5237-41
9164941
Annu Rev Immunol. 1999;17:189-220
10358757
Blood. 2004 Apr 1;103(7):2860-1; author reply 2862
15033884
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2003 Oct;20(5):396-9
14556191
Blood. 2003 Aug 1;102(3):814-9
12689936
Immunol Rev. 2002 Oct;188:9-21
12445277
Blood. 2002 Sep 15;100(6):1935-47
12200350
Br J Haematol. 2003 Oct;123(2):323-6
14531915
Bone Marrow Transplant. 2000 Aug;26(3):287-90
10967567
Eur J Immunol. 1994 Oct;24(10):2294-8
7925558
Immunogenetics. 2001;52(3-4):195-205
11220621
Transplantation. 1999 Jul 15;68(1):87-8
10428273
Tissue Antigens. 2001 Apr;57(4):358-62
11380947
Tissue Antigens. 2001 Mar;57(3):221-9
11285130
Blood. 2002 Nov 15;100(10):3825-7
12393440
Biol Blood Marrow Transplant. 1997 Jun;3(2):65-75
9267666
Science. 2002 Mar 15;295(5562):2097-100
11896281
Blood. 2004 Feb 15;103(4):1521-6
14504099
J Exp Med. 2004 Oct 18;200(8):957-65
15477349
Nature. 1986 Feb 20-26;319(6055):675-8
3951539
Nat Rev Immunol. 2003 Feb;3(2):108-22
12563295
Blood. 1999 Jul 1;94(1):333-9
10381530
Blood. 1999 Jul 15;94(2):434-41
10397710
Adv Immunol. 1989;47:187-376
2683611
Transplantation. 1995 Jun 27;59(12):1734-6
7604444
J Immunol. 2002 Nov 1;169(9):5118-29
12391228
Immunity. 1997 Dec;7(6):753-63
9430221
J Exp Med. 1994 Oct 1;180(4):1235-42
7931060
Exp Mol Pathol. 2004 Apr;76(2):90-8
15010286
Curr Opin Immunol. 2004 Oct;16(5):634-43
15342011
J Clin Invest. 1998 May 1;101(9):1835-42
9576746
J Immunol. 2001 Mar 1;166(5):2992-3001
11207248
Blood. 2003 Aug 15;102(4):1389-96
12714493
Transplantation. 1999 Dec 15;68(11):1784-9
10609957
Nat Rev Immunol. 2004 Mar;4(3):190-8
15039756
Cytotherapy. 2001;3(6):467-81
11953031
Eur J Immunogenet. 2003 Jun;30(3):213-21
12787000
Tissue Antigens. 2004 Mar;63(3):204-11
14989709